Establishing minimum clinically important difference values for the Patient-Reported Outcomes Measurement Information System Physical Function, hip disability and osteoarthritis outcome score for joint reconstruction, and knee injury and osteoarthritis out

AIM To establish minimum clinically important difference(MCID) for measurements in an orthopaedic patient population with joint disorders.METHODS Adult patients aged 18 years and older seeking care for joint conditions at an orthopaedic clinic took the Patient-Reported Outcomes Measurement Information System Physical Function(PROMIS~? PF) computerized adaptive test(CAT), hip disability and osteoarthritis outcome score for joint reconstruction(HOOS JR), and the knee injury and osteoarthritis outcome score for joint reconstruction(KOOS JR) from February 2014 to April 2017. MCIDs were calculated using anchorbased and distribution-based methods. Patient reports of meaningful change in function since their first clinic encounter were used as an anchor.RESULTS There were 2226 patients who participated with a mean age of 61.16(SD = 12.84) years, 41.6% male, and 89.7% Caucasian. Mean change ranged from 7.29 to 8.41 for the PROMIS~? PF CAT, from 14.81 to 19.68 for the HOOS JR, and from 14.51 to 18.85 for the KOOS JR. ROC cut-offs ranged from 1.97-8.18 for the PF CAT, 6.33-43.36 for the HOOS JR, and 2.21-8.16 for the KOOS JR. Distribution-based methods estimated MCID values ranging from 2.45 to 21.55 for the PROMIS~? PF CAT; from 3.90 to 43.61 for the HOOS JR, and from 3.98 to 40.67 for the KOOS JR. The median MCID value in the range was similar to the mean change score for each measure and was 7.9 for the PF CAT, 18.0 for the HOOS JR, and 15.1 for the KOOS JR.CONCLUSION This is the first comprehensive study providing a wide range of MCIDs for the PROMIS? PF, HOOS JR, and KOOS JR in orthopaedic patients with joint ailments.

Chondroitin sulfate and glucosamine combination in patients with knee and hip osteoarthritis:A long-term observational study in Russia

BACKGROUND Oral treatment of glucosamine(GA) combined with chondroitin sulfate(CS) was reportedly effective for pain relief and function improvement in osteoarthritis patients with moderate to severe knee pain in clinical trials. While the effectiveness of GA and CS on both clinical and radiological findings has been demonstrated, only a few high-quality trials exist. Therefore, controversy regarding their effectiveness in real-world clinical practice remains.AIM To investigate the impact of GA + CS on clinical outcomes of patients with knee and hip osteoarthritis in routine clinical practice.METHODS A multicenter prospective observational cohort study included 1102 patients of both genders with knee or hip osteoarthritis(Kellgren & Lawrence grades Ⅰ-Ⅲ) in 51 clinical centers in the Russian Federation from November 20, 2017, to March 20,2020, who had started to receive oral capsules of glucosamine hydrochloride 500 mg and CS 400mg according to the approved patient information leaflet starting from 3 capsules daily for 3 wk,followed by a reduced dosage of 2 capsules daily before study inclusion(minimal recommended treatment duration is 3-6 mo). Changes in subscale scores [Pain, Symptoms, Function, and Quality of Life(QOL)] of the Knee Injury and Osteoarthritis Outcome Score(KOOS)/Hip Disability and Osteoarthritis Outcome Score(HOOS) questionnaires during the observational period(up to 54-64wk with a total of 4 visits). Patients’ treatment satisfaction, data on the combined oral use of glucosamine hydrochloride and CS, concomitant use of non-steroidal anti-inflammatory drugs(NSAIDs), and adverse events(AEs) were also evaluated.RESULTS A total of 1102 patients with knee and hip osteoarthritis were included in the study. The mean patient age was 60.4 years, most patients were women(87.8%), and their average body mass index was 29.49 kg/m2. All subscale scores(Pain, Symptoms, Function, and QOL) of the KOOS and HOOS demonstrated clinically and statistically significant improvements. In patients with knee osteoarthritis, the mean score increases from baseline to the end of Week 64 were 22.87, 20.78,16.60, and 24.87 on Pain, Symptoms, Physical Function(KOOS-PS), and QOL subscales(P < 0.001for all), respectively. In patients with hip osteoarthritis, the mean score increases were 22.81, 19.93,18.77, and 22.71 on Pain, Symptoms, Physical Function(HOOS-PS), and QOL subscales(P < 0.001for all), respectively. The number of patients using any NSAIDs decreased from 43.1% to 13.5%(P < 0.001) at the end of the observation period. Treatment-related AEs occurred in 2.8% of the patients and mainly included gastrointestinal disorders [25 AEs in 24(2.2%) patients]. Most patients(78.1%) were satisfied with the treatment.CONCLUSION Long-term oral GA + CS was associated with decreased pain, reduced concomitant NSAID therapy, improved joint function and QOL in patients with knee and hip osteoarthritis in routine clinical practice.

基于快速康复理念的线上线下整体优化干预在伴肌少症老年全髋关节置换术患者中的应用效果

目的探讨基于快速康复理念的线上线下整体优化干预在伴肌少症老年全髋关节置换术(THA)患者中的应用效果。方法选取2021年4月—2023年4月收治的104例伴肌少症老年THA,根据干预方法不同分为对照组、观察组,各52例。对照组予以常规围手术期干预,在此基础上,观察组予以基于快速康复理念的线上线下整体优化干预。对比2组住院情况、不良事件发生率、依从性、视觉模拟评分法(VAS)、简易躯体执行能力测试量表(SPPB)、髋关节伤残和骨关节炎问卷(HOOS)、Harris髋关节功能及Barthel指数评分。结果观察组首次下床时间、首次排便时间、住院时间均短于对照组(P<0.01);观察组术后3 d、术后7 d VAS评分均低于对照组(P<0.05);观察组不良事件总发生率3.85%(2/52)低于对照组17.31%(9/52)(P<0.05);观察组总依从度96.15%(50/52)高于对照组78.85%(41/52)(P<0.01);术后1个月、3个月观察组SPPB、HOOS及Harris、Barthel指数评分均较对照组高(P<0.05)。结论基于快速康复理念的线上线下整体优化干预应用于伴肌少症老年THA患者中,可降低患者术后疼痛感,减少不良事件,提升依从性,促进髋关节及躯体功能好转,有助于患者预后恢复。

股骨髋臼撞击征关节镜手术后磁共振成像结果与疼痛的关系研究

目的探讨股骨髋臼撞击征(FAI)关节镜手术后磁共振成像(MRI)结果与疼痛的关系。方法前瞻性地连续募集计划行关节镜手术的FAI患者42例(43个髋关节)。采用3.0T MRI获取术前和术后MRI图像。采用髋关节残疾与骨关节炎结果评分(HOOS)评估疼痛变化情况。采用术后MRI图像评估髋关节成形术、股骨成形术、软骨和盂唇修复术、骨髓水肿、软骨下囊肿、软骨缺陷、盂唇撕裂、囊部缺陷和渗出情况,并分析最佳检测方位。结果髋臼清理术长度增加与HOOS改善有关(OR:-2.07,95%CI:-3.53~-0.62,P=0.008),而其他成像结果与HOOS改善无相关性。股骨成形术和关节囊改变斜轴位检测效果最好,而髋臼成形术、软骨和盂唇修复术矢状位检测效果最好。MRI反映盂唇修复术后变化的敏感性和特异性均为100.0%,反映股骨成形术后变化的敏感性为97.7%。MRI反映髋臼成形术后变化的敏感性和特异性分别为83.3%和75.0%。MRI反映软骨修复术后变化的敏感性和特异性分别为75.0%和54.3%。结论关节镜下髋臼成形术与术后疼痛相关。